A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

计划入组 1,202 人 · 首次发布于 2024 年 5 月 31 日

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

计划入组 41 人 · 首次发布于 2021 年 3 月 11 日

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

计划入组 45,789 人 · 首次发布于 2022 年 9 月 14 日

Bivalent influenza modRNA vaccine(BioNTech/Pfizer)

modRNA monovalent influenza vaccine (Pfizer)

BNT-161

Moderna, Inc.

United States

Moderna US, Inc.

United States

Modra Pharmaceuticals BV

Netherlands

mRNA Therapy Reactivates Developmental Gene to Repair Heart Damage After Heart Attack

Pfizer-BioNTech Launches Landmark Phase 3 Trial for mRNA-Based Influenza Vaccine

Novel Research Reveals UCHL1 as Therapeutic Target in Ovarian Cancer and Western Diet's Impact on Liver Cancer